Proteomics International Laboratories Ltd
ASX:PIQ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Hormel Foods Corp
NYSE:HRL
|
Food Products
|
| US |
|
Philip Morris International Inc
NYSE:PM
|
Tobacco
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
Procter & Gamble Co
NYSE:PG
|
Consumer products
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Booking Holdings Inc
NASDAQ:BKNG
|
Hotels, Restaurants & Leisure
|
| US |
|
Intel Corp
NASDAQ:INTC
|
Semiconductors
|
| US |
|
Match Group Inc
NASDAQ:MTCH
|
Media
|
| US |
|
Apple Inc
NASDAQ:AAPL
|
Technology
|
| US |
|
NVIDIA Corp
NASDAQ:NVDA
|
Semiconductors
|
| US |
|
Alphabet Inc
NASDAQ:GOOGL
|
Media
|
| US |
|
Meta Platforms Inc
NASDAQ:META
|
Media
|
| US |
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.565
1.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Hormel Foods Corp
NYSE:HRL
|
US |
|
|
Philip Morris International Inc
NYSE:PM
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
Procter & Gamble Co
NYSE:PG
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Booking Holdings Inc
NASDAQ:BKNG
|
US |
|
|
Intel Corp
NASDAQ:INTC
|
US |
|
|
Match Group Inc
NASDAQ:MTCH
|
US |
|
|
Apple Inc
NASDAQ:AAPL
|
US |
|
|
NVIDIA Corp
NASDAQ:NVDA
|
US |
|
|
Alphabet Inc
NASDAQ:GOOGL
|
US |
|
|
Meta Platforms Inc
NASDAQ:META
|
US |
|
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
US |
This alert will be permanently deleted.
Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd
Net Issuance of Common Stock
Proteomics International Laboratories Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Net Issuance of Common Stock
AU$6.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
|
Anteotech Ltd
ASX:ADO
|
Net Issuance of Common Stock
AU$10.5m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
4%
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Net Issuance of Common Stock
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Net Issuance of Common Stock
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genetic Signatures Ltd
ASX:GSS
|
Net Issuance of Common Stock
AU$37.5m
|
CAGR 3-Years
513%
|
CAGR 5-Years
171%
|
CAGR 10-Years
N/A
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Proteomics International Laboratories Ltd
Glance View
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
See Also
What is Proteomics International Laboratories Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
6.6m
AUD
Based on the financial report for Jun 30, 2024, Proteomics International Laboratories Ltd's Net Issuance of Common Stock amounts to 6.6m AUD.
What is Proteomics International Laboratories Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
124%
Over the last year, the Net Issuance of Common Stock growth was -39%. The average annual Net Issuance of Common Stock growth rates for Proteomics International Laboratories Ltd have been 5% over the past three years , 124% over the past five years .
You don't have any saved screeners yet
